Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Northbound Flows: Big Sell on CATL After May Holiday

Northbound Flows: Moutai, Zijin, Great Wall Motor

Northbound Flows: CMB, China Yangtze Power, BYD, Longi Green Energy, SF Holding

Northbound Flows: CMB Big Sell After CEO Scandal

Northbound Flows: Moutai, CSCC, Beijing Oriental Yuhong, Sungrow

Northbound Flows: Sungrow Power, Hengrui, Ganfeng, Cosco Shipping

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

China Consumer discretionary / Quantitative Analysis

<ul>
<li>We analyze the weekly Shanghai/Shenzhen northbound Connect flows with our data engine.</li>
<li>Industrial, healthcare and consumer discretionary led the inflow while financials led the outflow.</li>
<li>We highlight inflows into Shenzhen Inovance and Nari Technology that worth investor attention. </li>
</ul>


We analyze the weekly Shanghai/Shenzhen northbound Connect flows with our data engine.
Industrial, healthcare and consumer discretionary led the inflow while financials led the outflow.
We highlight inflows into Shenzhen Inovance and Nari Technology that worth investor attention. 


Shenzhen Inovance Technology Co., (300124 CH)

Northbound Flows: Shenzhen Inovance, Nari Technology